Chong Kun Dang Pharmaceutical
PharmaSeoul, South Korea, South Korea · Est. 1953
Chong Kun Dang Pharmaceutical is a South Korean pharmaceutical company that develops and manufactures prescription drugs and over-the-counter medicines across multiple therapeutic areas.
5
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
14
Indications↗
Distinct diseases across all programs
295
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
5 drugs in development
Approved1
Phase 33
Phase 12
Preclinical1
By Therapeutic Area
top 5
Metabolic & Endocrine
338%
Cardiovascular
113%
Ophthalmology
113%
Dermatology
113%
Oncology
113%
R&D Momentum
56/100
Pipeline Velocity
34/100
Trial Completion Rate
100/100
Pipeline Concentration
22/100
Pipeline Freshness
37/100
Strategic Signals
- ↗Active in Cardiovascular but thin pipeline — potential licensing opportunity
Activity
Key Events
Mar 1, 2026TrialEvaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients
Mar 1, 2026TrialA First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
Feb 23, 2026TrialA Clinical Trial to Compare and Evaluate Evaluate the Pharmacokinetics and Safety of CKD-846
Feb 9, 2026TrialA Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and EU-Dupixent® in Healthy Adult Participants.
Nov 26, 2025TrialPharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (Risankizumab Biosimilar), With EU-approved Skyrizi®, and US-licensed Skyrizi® in Healthy Adult Participants
Oct 30, 2025TrialClinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy Volunteers
Oct 28, 2025TrialClinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy Volunteers
Oct 24, 2025TrialClinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers
4 more events
Oct 16, 2025TrialPhase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Aug 14, 2025TrialOptimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
May 14, 2025TrialA Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants
May 12, 2025TrialInitial Pilot Study to Evaluate the Safety and Temporary Symptom Improvement Efficacy of CKD-981
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Therapeutic Focus
OncologyCardiovascularGastrointestinalRespiratory
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Cardiovascular
Dermatology
Metabolic & Endocrine
Ophthalmology
Cardiovascular
Cardiovascular Disease
AmarylApproved
Dermatology
Metabolic & Endocrine
Diabetes Mellitus
AmarylPhase 3
Obesity
ThiazolidinedionePhase 1
Type 2 Diabetes
AmarylApproved
ThiazolidinedionePhase 3
Type 2 Diabetes Mellitus
AmarylApproved
ThiazolidinedionePhase 3
Oncology
Ophthalmology
Diabetic Macular Edema
AmarylApproved
Unknown / Other
Showing 15 of 16 programs
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)